Condition

Urothelial Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 30 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials30
Recruiting6
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

30 shown
DK222 Study at HopkinsNCT07140315 · 2027-01-31
RECRUITING
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersNCT07545122 · 2026-09-01
RECRUITING
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168 · 2025-11-07
RECRUITING
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)NCT07038343 · 2025-06-04
RECRUITING
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesNCT04923178 · 2022-10-24
RECRUITING
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · 2022-09-06
RECRUITING
Tucatinib Continuation StudyNCT07768358 · 2026-11-06
NOT_YET_RECRUITING
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationNCT06448364 · 2024-05-09
TERMINATED
A Study of ADRX-0706 in Select Advanced Solid TumorsNCT06036121 · 2023-09-26
ACTIVE_NOT_RECRUITING
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsNCT05233436 · 2022-02-24
TERMINATED
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)NCT05259696 · 2022-02-11
COMPLETED
Study of INCB086550 in Select Solid TumorsNCT04629339 · 2021-09-02
TERMINATED
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesNCT04235777 · 2020-07-13
ACTIVE_NOT_RECRUITING
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic SurgeryNCT07413120 · 2020-05-07
COMPLETED
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018 · 2019-11-13
TERMINATED
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionNCT04180371 · 2019-11-07
ACTIVE_NOT_RECRUITING
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.NCT03983954 · 2019-10-10
ACTIVE_NOT_RECRUITING
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)NCT04044859 · 2019-08-20
ACTIVE_NOT_RECRUITING
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)NCT03472560 · 2018-05-02
TERMINATED
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid TumorsNCT03576131 · 2018-04-30
TERMINATED
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced MalignanciesNCT03317496 · 2017-12-21
TERMINATED
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaNCT03207867 · 2017-08-28
TERMINATED
A Phase I Trial of LY3143921 Hydrate in Solid TumoursNCT03096054 · 2017-06-21
COMPLETED
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsNCT02661100 · 2017-01-01
WITHDRAWN
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerNCT02769962 · 2016-05-09
TERMINATED
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)NCT02393248 · 2015-02-27
TERMINATED
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)NCT02335424 · 2015-02-24
COMPLETED
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)NCT02256436 · 2014-10-22
COMPLETED
A Study of TAS-120 in Patients With Advanced Solid TumorsNCT02052778 · 2014-07-21
COMPLETED
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveNCT02111850 · 2014-02-07
COMPLETED

Common interventions

PembrolizumabDRUG3CisplatinDRUG2DocetaxelDRUG2pembrolizumabBIOLOGICAL2SasanlimabBIOLOGICAL2[18F]DK222 radiotracerDRUG15-FluorouracilDRUG1ADRX-0706DRUG1AldesleukinDRUG1Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)BIOLOGICAL1Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeksGENETIC1Avelumab (MSB0010718C)DRUG1Avelumab 1200 mg in combination with gemcitabine/cisplatinDRUG1Avelumab 1200 mg in combination with pemetrexed/carboplatinDRUG1Avelumab 800 mg in combination with gemcitabine / cisplatin.DRUG1Avelumab 800 mg in combination with pemetrexed / carboplatinDRUG1AVZO-1418DRUG1Axitinib (AG-013736)DRUG1BevacizumabDRUG1bevacizumabBIOLOGICAL1BiopsyPROCEDURE1Bone scanDIAGNOSTIC_TEST1BT5528DRUG1CapecitabineDRUG1CarboplatinDRUG1

Trial status mix

TERMINATED10
COMPLETED7
RECRUITING6
ACTIVE_NOT_RECRUITING5
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

PHASE121
PHASE215
PHASE32
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.